AOAnna Olszewska

Anna Olszewska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna Olszewska has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Etiology, Epidemiology, and Therapeutic Approaches for Primary Sclerosing Cholangitis in the Context of Concurrent Non-specific Inflammatory Bowel Diseases

    by Anna Olszewska, Karolina Matyja, Aleksandra Berner, Katarzyna Stencel, Karina Stelmaszak, Klaudia Marczyk, Paulina Polak, Maciej Pękała, Monika Polaszek, Marta Bogowska

    Introduction: Primary sclerosing cholangitis (PSC) is a chronic, idiopathic disease characterized by persistent and progressive inflammation of the intrahepatic and/or extrahepatic bile ducts. This leads to fibrosis, cholestatic complications, and liver failure. In over 70% of patients, non-specific intestinal inflammations coexist, particularly ulcerative colitis, and sporadically Crohn's disease. Aim: Our study aimed to assess current literature on primary sclerosing cholangitis (PSC), covering its causes, symptoms, treatment methods, and the connection between PSC and inflammatory bowel disease (IBD) co-occurrence. Materials and methods: We conducted a PubMed literature review using keywords like "primary sclerosing cholangitis pathogenesis," "primary sclerosing cholangitis and inflammatory bowel disease," and "primary sclerosing cholangitis and ulcerative colitis.” Results: Our research extensively covered PSC epidemiology, pathogenesis, and treatment options. Emphasis was placed on the heightened prevalence of inflammatory bowel diseases, including ulcerative colitis, among PSC patients. Summary: Primary sclerosing cholangitis (PSC) is a disease causing gradual damage to bile ducts within or outside the liver. Over 70% of patients also experience inflammatory bowel disease (IBD), mainly ulcerative colitis. The exact causes of PSC and its connection to IBD remain unclear. The theories involve hyperactive "intestinal" T cells or the impact of gut microbiome on their growth. Presently, a liver transplant stands as the sole remedy.


  • Open Access

    SGLT2 inhibitors - a breakthrough in treatment of heart failure and their multipotential beneficial role in cardiology, diabetology, nephrology and neurology

    by Marta Bogowska, Aleksandra Berner, Klaudia Marczyk, Karolina Matyja, Anna Olszewska, Maciej Pękała, Paulina Polak, Monika Polaszek, Karina Stelmaszak, Katarzyna Stencel

    Inhibitors of the sodium-glucose cotransporter 2 (SGLT2 inhibitors) are relatively new and innovative antihyperglycemic drugs which by inhibiting sodium-glucose cotransporter 2 minimalise reabsorption of glucose in nephrones. Due to this process, SGLT2 inhibitors became a first-choice drugs in diabetology. Flozins were a turning point in many clinical trials and currently consequently conquer pharmacoterapy in cardiology. In the past years, clinical studies proved vast role of SGLT2 inhibitors in other fields of medicine. Flosins protect heart muscle and kidneys among patients with or without type diabetes mellitus type 2. They have positive effect on hypertension, arteries and brain tissue. Cardiological condition with the lowest long-term outcome in patients is heart failure with reduced ejection fraction. Until flozins, treatment in heart failure with reduced ejection fraction was based on four groups of drugs: β-blocker, inhibitors of the renin-angiotensin aldosterone system (RAA), including angiotensin converting enzyme ACE/ARB inhibitors, angiotensin and neprilysin receptor blockers (ARNI) and mineralocorticoid receptor antagonists (MRA). It was an appropriate HFrEF treatment over the last years. However thanks to large-scale researches a role of flozins in cardiology have been established and they became hope for a change in the course of heart failure. The following article presents aspects of using flozins in treatment of patients with HFrEF, multipotential usage, vast benefits for patients, not solely cardiologic, and side effects of these miraculous group of drugs.


  • Open Access

    One step closer – the impact of daily step count on health and how many steps should be taken per day

    by Paulina Polak, Monika Polaszek, Katarzyna Stencel, Aleksandra Berner, Maciej Pękała, Anna Olszewska, Karina Stelmaszak, Marta Bogowska, Karolina Matyja, Klaudia Marczyk

    Introduction: Physical activity is an essential component of a healthy lifestyle. Walking is an open-accessed form of physical activity that requires no specialized equipment and can be performed at practically any moment of the day. In recent years, it has gained increasing interest and stands out as one of the most widely recommended forms of exercise. Since the beginning of the 21st century, the number of studies focusing on the impact of mean daily step count on health has been growing each year, with a significant surge observed since 2017. Undoubtedly, this topic is relevant to current health trends. Hitherto, there are no evidence-based recommendations regarding the number of steps that should be taken per day. Within this review, we conducted an analysis on the impact of daily step count on the risk of death and the incidence of selected diseases. Aim of the study: The aim of our study is to review of current literature on the influence of daily step count on both physical and mental health. Materials and Methods: We reviewed the literature available in PubMed, using the key words: „daily step count”, „step count mental health”, „ physical activity”, „pedometr”. Results: The daily step count can prominently impact the improvement and maintenance of human health and significant health benefits can be achieved by taking 4000-10000 steps per day. Summary: Research has shown that individuals who take more steps throughout the day are less prone to certain diseases, experience milder symptoms, exhibit better overall physical fitness, and have a lower risk of all-cause mortality. In the upcoming years, we can expect further studies aimed at identifying the most optimal daily step count.


  • Open Access

    Physical activity of patients with chronic kidney disease

    by Klaudia Marczyk, Aleksandra Berner, Katarzyna Stencel, Maciej Pękała, Anna Olszewska, Karina Stelmaszak, Paulina Polak, Monika Polaszek, Marta Bogowska, Karolina Matyja

    Introduction: The main causes of chronic kidney disease (CKD) are diabetic and hypertensive nephropathy. The incidence of civilization diseases is increasing, which also indirectly affects the increase in the incidence of CKD. The patient's therapy after the diagnosis should include the care of a multi-specialist therapeutic team that will remove as many restrictions as possible in everyday functioning and ensure a high quality of life. In addition to the selection of individual renal replacement therapy, i.a. physical rehabilitation. Despite the fact that in the course of chronic kidney disease physical activity is impaired by numerous pathophysiological processes, the patient should be encouraged to undertake physical activity in order to reduce the risk of death due to cardiovascular diseases, as well as to eliminate many other adverse health effects of the disease. The following paper aims to analyze the impact of physical activity on CKD patients and the pathophysiological causes of low physical activity in this group of patients and the possibility of implementing rehabilitation as an element of comprehensive therapy. Aim of the study: To review the current literature on the physical activity of patients with chronic kidney disease Materials and Methods: A review of the publications available in PubMed, using the key words „chronic kidney disease”, „psychical activity in chronic kidney disease”, physical activity”, „kidney failure”, „dialysis”, „renal rehabilitation”, „quality of life”


  • Open Access

    Indications of Platelet-Rich Plasma (PRP) in Dermatology

    by Aleksandra Berner, Katarzyna Stencel, Maciej Pękała, Anna Olszewska, Karina Stelmaszak, Paulina Polak, Monika Polaszek, Marta Bogowska, Karolina Matyja, Klaudia Marczyk

    Introduction: PRP is an autologous serum containing high concentrations of platelets and growth factors. It is used in dermatology for a variety of purposes, including hair growth, skin renewal, the removal of acne scars, dermal augmentation, and the treatment of striae distensae. The origins of PRP trace back to the 1970s, originating within the field of hematology as a treatment for patients grappling with thrombocytopenia. The subsequent decades, specifically the 1980s and 1990s, witnessed the integration of PRP into surgical procedures, notably in maxillofacial and plastic surgeries. The rationale underlying the employment and therapeutic potential of a concentrated platelet solution hinges upon their remarkable ability to furnish elevated levels of vital growth factors, thus instigating a regenerative impetus that facilitates repair in tissues characterized by limited innate healing capabilities. This comprehensive review delves into the multifaceted facets of PRP, encompassing mechanisms of action, prevailing indications, existing clinical substantiation, safety considerations, and the burgeoning spectrum of potential applications within the domain of skin condition treatments. Aim of the study: To review the current literature on the use of PRP in the field of dermatology Materials and Methods: We reviewed the literature available in PubMed, using the key words “platelet rich plasma”, “prp”, “autologous platelet rich plasma”, “alopecia”, “anti-aging” Results: PRP has a lot of potential in dermatology and its therapeutic uses are growing. Future research should standardize PRP therapy procedures for particular reasons. Summary: The versatile action of PRP has made it the subject of intense research. However, the reports in the literature to date on its use require further studies on larger groups of people to confirm its effects.

  • Open Access

    Paraneoplastic syndromes in dermatology - cutaneous manifestations of internal malignancy

    by Karolina Matyja, Aleksandra Berner, Katarzyna Stencel, Maciej Pękała, Anna Olszewska, Karina Stelmaszak, Klaudia Marczyk, Paulina Polak, Monika Polaszek, Marta Bogowska

    Introduction: Cutaneous manifestations linked with internal malignancies can exhibit a wide range of appearances.The ideal paraneoplastic marker is one that exclusively appears with a tumor, vanishes upon tumor treatment, and can potentially reemerge with tumor recurrence or metastasis. They are divided into two main categories: acquired and genetic conditions. Among acquired paraneoplastic syndromes a few are strongly correlated with internal malignancies, others have less pronounced associations. Aim of the study: To review the current literature on the topic of dermatological paraneoplastic syndromes. Materials and Methods: We reviewed the literature available in PubMed, using the key words: “paraneoplastic syndromes”, “paraneoplastic dermatoses”, “paraneoplastic syndromes in dermatology”. Results: We presented the most common, selected skin paraneoplastic syndromes. We indicated the types of neoplasms associated with these dermatoses and described their clinical appearance along with potential mechanisms of development. Summary: Timely recognition of paraneoplastic skin manifestations is crucial as they can provide an opportunity for diagnosing and treating the underlying neoplasm. That’s why dermatologists and clinicians should be familiar with this topic to perform an early diagnosis of the underlying malignancy.

  • Open Access

    Myocarditis as a cause of neonate’s circulatory failure during delivery - case study

    by Maciej Pękała, Katarzyna Stencel, Aleksandra Berner, Anna Olszewska, Karina Stelmaszak, Paulina Polak, Monika Polaszek, Marta Bogowska, Karolina Matyja, Klaudia Marczyk

    Myocarditis (MCI) is a heart pathology characterized by its rare occurrence and a possible fatal course. In the natural history of the disease inflammatory cell infiltrates are present. There are subtypes of MCI depending on the predominant cell type in the biopsy sampls. One of them is eosinophilic myocarditis. In eosinophilic myocarditis more that 50% of the cells are eosinophils. In the later phases of the disease the myocardium is infiltrated by fibrous tissue and the heart vessels are often affected by thrombosis. Cardiomyopathy is a common long-term complication of the MCI. Reported case presents a death of a male neonate. The neonate was delivered by vaginal delivery. Both prenatal development and all the prenatal tests indicated proper development of the fetus. At the delivery the neonate weight was 3900 grams and was evaluated with only 1 point on the Apgar score. Moreover, the neonate presented a complete acute cardiorespiratory failure at birth. Despite the 2 hour-long cardio-pulmonary resuscitation no return of spontaneous circulation was observed. The neonate’s remains were pathologically as well as histologically examined. The microscopic examination of the neonate’s heart samples contained many inflammatory cell infiltrations. Microabscesses with Charcot-Leyden crystals inside were also observed. Furthermore, the presence of atypical, polynuclear cells was noted. On the basis of the morphological image, it was recognized as an eosinophilic MCI.